Literature DB >> 29551621

Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy.

John L Schomburg1, Suprita Krishna1, Katherine J Cotter1, Ayman Soubra1, Amrita Rao1, Badrinath R Konety2.   

Abstract

OBJECTIVE: To determine the preoperative incidence of subclinical lower-extremity deep vein thrombosis (DVT), as well as to evaluate the utility of preoperative DVT screening in patients with bladder cancer before undergoing radical cystectomy.
MATERIALS AND METHODS: Beginning in 2014, we prospectively instituted a policy of obtaining a screening lower-extremity duplex ultrasound on all patients within 7 days before undergoing radical cystectomy. We reviewed the electronic medical records of all patients at our institution who underwent radical cystectomy for bladder cancer from January 2012 through December 2015. The screened group (n = 65) underwent preoperative screening; the historical control group (n = 78) did not. Primary outcome was a lower-extremity duplex ultrasound positive screening. Secondary outcome measures included the development of symptomatic venous thromboembolism (VTE) postoperatively, and the rate and severity of complications.
RESULTS: DVT was identified in 13.9% of patients before undergoing cystectomy. Univariate analysis demonstrated an increased risk of subclinical DVT in patients who were exposed to neoadjuvant chemotherapy (35.3% vs 5.1%, P = .008). Postoperatively, there was a nonsignificant trend of lower DVT rate in the screened group compared to historical control. Overall complication rate and severity were similar between the groups.
CONCLUSION: Subclinical DVT is present in a significant number of pre-cystectomy patients, especially those exposed to neoadjuvant chemotherapy. Ultrasound screening in patients before undergoing radical cystectomy may identify opportunities for early intervention to reduce morbidity and mortality associated with perioperative DVT or venous thromboembolism in the cystectomy population.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29551621     DOI: 10.1016/j.urology.2018.01.052

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer.

Authors:  Andrew Amenyogbe; Francis Lemire; David Yachnin; Marc Carrier; Kristen McAlpine; Rodney H Breau; Dominick Bossé; Tzu-Fei Wang; Christopher Morash; Ilias Cagiannos; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

2.  Dimethyl 2,2'-[2,2'-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect.

Authors:  Yaonan Wang; Haiyan Chen; Xiaoyi Zhang; Lin Gui; Jianhui Wu; Qiqi Feng; Shiqi Peng; Ming Zhao
Journal:  Int J Nanomedicine       Date:  2018-11-22

3.  Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery.

Authors:  Shuichi Tatarano; Hideki Enokida; Masaya Yonemori; Rumiko Eura; Hirofumi Yoshino; Hiroaki Nishimura; Yasutoshi Yamada; Masayuki Nakagawa
Journal:  Investig Clin Urol       Date:  2021-03

Review 4.  Current thromboprophylaxis in urological cancer patients during COVID-19 pandemic.

Authors:  Adam Ostrowski; Piotr Skrudlik; Filip Kowalski; Paweł Lipowski; Magdalena Ostrowska; Przemysław Adamczyk; Jan Adamowicz; Tomasz Drewa; Kajetan Juszczak
Journal:  Cent European J Urol       Date:  2022-04-14

5.  Decreasing incidence of venous thromboembolic events after radical cystectomy: are we finally improving?

Authors:  Benjamin T Harper; Christopher J D Wallis; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.